Osstyn, Sander L. http://orcid.org/0009-0007-4324-6114
Handels, Ron
Boots, Lizzy M. M.
Balvert, Sanne C. E.
Evers, Silvia M. A. A.
de Vugt, Marjolein E.
Funding for this research was provided by:
ZonM (80-85200-98-21039)
Article History
Received: 28 March 2023
Accepted: 29 May 2023
First Online: 22 June 2023
Declarations
:
: The Medical Ethics Review Committee of Maastricht University stated that the Medical Research Involving Human Subjects Act (WMO) did not apply to this study and that its official approval was thus not required (number: METC 2021–2955). This implies that the research can be performed. Written, informed consent to participate will be obtained from all participants and participants can opt out the study at any time without a reason.
: The participant information materials and informed consent form are available from the corresponding author on request.
: Part of the Partner in Balance intervention user license fee is paid to the Alzheimer Center Limburg of Maastricht University both within and outside the study, used for continuous development of the intervention. Authors S.L. Osstyn, L.M.M Boots, S.C.E. Balvert, S.M.A.A. Evers, and M.E. de Vugt declare no competing interests. R. Handels declares no competing interests related to this study; R. Handels declares the following outside this study: consulting fees (paid to the department) from Lilly Nederland B.V. (advisory; 2022), the institute for Medical Technology Assessment (advisory; 2021; content initiated by Biogen), Biogen Netherlands BV (advisory; 2021), Biogen MA Inc. (advisory; 2020), and Eisai Inc. (advisory; 2019).